• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胃肠道和胰腺神经内分泌肿瘤的临床表现和诊断延误。

Presenting Symptoms and Delay in Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumours.

机构信息

King's College London, London, United Kingdom.

Neuroendocrine Tumour Patients Foundation, Leamington Spa, United Kingdom.

出版信息

Neuroendocrinology. 2018;107(1):42-49. doi: 10.1159/000488510. Epub 2018 Mar 18.

DOI:10.1159/000488510
PMID:29550809
Abstract

The gastrointestinal tract and pancreas are common primary sites for neuroendocrine tumours (NETs). Patients often report a long duration of non-specific symptoms in the year prior to diagnosis. The aims of this study were, firstly, to establish pre-diagnosis patterns of symptoms, and secondly, to determine the time from onset of symptoms to NET diagnosis and understand the interaction with primary and secondary healthcare providers. A survey was designed on a web-based survey platform with the focus on patient symptoms prior to diagnosis and a screen for functional diarrhoea (Rome III criteria [C4]). A total of 303 responses were received. The median duration from the time of first symptoms to diagnosis was 36 months for small bowel NETs and 24 months for pancreatic NETs. Common first symptoms were pain (36%), flushing (24%), and diarrhoea (24%); 29% of small bowel NET respondents were given an initial diagnosis of irritable bowel syndrome. Dyspepsia was the second most common initial incorrect diagnosis. Respondents saw their GP 5 times over a median 18-month period for their symptoms; 31% of patients were diagnosed following unplanned emergency admission. In conclusion, this survey demonstrates a median time to diagnosis of 36 months for patients with small bowel NETs. Incorrect initial diagnosis appears to be very common, with a high number of attendances in primary and secondary care prior to a correct diagnosis being made. An earlier diagnosis may improve patients' quality of life and possible survival.

摘要

胃肠道和胰腺是神经内分泌肿瘤 (NETs) 的常见原发部位。患者在诊断前往往会有很长一段时间出现非特异性症状。本研究的目的首先是确定诊断前症状的模式,其次是确定从症状出现到 NET 诊断的时间,并了解与初级和二级保健提供者的相互作用。我们设计了一个基于网络的调查平台,重点是诊断前患者的症状和功能性腹泻筛查(罗马 III 标准 [C4])。共收到 303 份回复。从小肠 NET 到诊断的中位时间为 36 个月,从胰腺 NET 到诊断的中位时间为 24 个月。常见的首发症状是疼痛(36%)、潮红(24%)和腹泻(24%);29%的小肠 NET 受访者最初被诊断为肠易激综合征。消化不良是第二常见的初始误诊。受访者在中位 18 个月的时间内,因症状共就诊 5 次;31%的患者是在非计划急诊入院后被诊断的。总之,这项调查表明,小肠 NET 患者的中位诊断时间为 36 个月。初始误诊似乎非常常见,在做出正确诊断之前,患者在初级和二级医疗保健机构就诊次数很多。早期诊断可能会提高患者的生活质量和可能的生存率。

相似文献

1
Presenting Symptoms and Delay in Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumours.胃肠道和胰腺神经内分泌肿瘤的临床表现和诊断延误。
Neuroendocrinology. 2018;107(1):42-49. doi: 10.1159/000488510. Epub 2018 Mar 18.
2
Delays and routes to diagnosis of neuroendocrine tumours.神经内分泌肿瘤的诊断延误和途径。
BMC Cancer. 2018 Nov 16;18(1):1122. doi: 10.1186/s12885-018-5057-3.
3
Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.SATB2 阳性可将 Islet1 阳性直肠神经内分泌肿瘤与胰十二指肠神经内分泌肿瘤区分开来。
J Clin Pathol. 2021 Sep;74(9):582-588. doi: 10.1136/jclinpath-2020-206645. Epub 2020 Sep 15.
4
Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation.胃肠胰神经内分泌肿瘤的诊断和治疗:前瞻性采集、回顾性分析的临床多中心研究的最新数据。
Oncologist. 2011;16(5):602-13. doi: 10.1634/theoncologist.2011-0002. Epub 2011 Apr 5.
5
Recent updates on grading and classification of neuroendocrine tumors.神经内分泌肿瘤分级与分类的最新进展
Ann Diagn Pathol. 2017 Aug;29:11-16. doi: 10.1016/j.anndiagpath.2017.04.005. Epub 2017 Apr 13.
6
Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.神经内分泌肿瘤患者腹泻的鉴别诊断:一项系统综述
World J Gastroenterol. 2020 Aug 14;26(30):4537-4556. doi: 10.3748/wjg.v26.i30.4537.
7
Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours.胃肠胰神经内分泌肿瘤的放射学和核医学影像。
Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):803-18. doi: 10.1016/j.bpg.2012.12.004.
8
Current status of Interventional Radiology in the management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs).介入放射学在胃肠胰神经内分泌肿瘤(GEP-NETs)治疗中的现状
Cardiovasc Intervent Radiol. 2015 Feb;38(1):13-24. doi: 10.1007/s00270-014-1005-z. Epub 2014 Nov 5.
9
Highlights in GEP-NETs From the 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease: Commentary.第13届神经内分泌肿瘤疾病诊断与治疗年度ENETS会议GEP-NETs亮点:评论
Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 7):17-9.
10
[Small bowel neuroendocrine tumours: to be considered in the differential diagnosis of unexplained abdominal pain and diarrhoea].[小肠神经内分泌肿瘤:在不明原因腹痛和腹泻的鉴别诊断中应予以考虑]
Ned Tijdschr Geneeskd. 2020 Jan 22;164:D4235.

引用本文的文献

1
Bone and muscle mass characteristics in patients with gastroenteropancreatic neuroendocrine neoplasms.胃肠胰神经内分泌肿瘤患者的骨量和肌肉量特征
Endocrine. 2025 Apr;88(1):348-358. doi: 10.1007/s12020-024-04140-4. Epub 2024 Dec 30.
2
Earlier diagnosis of small intestine neuroendocrine tumours (SI-NETs) through transformation of the South Wales NET service.通过南威尔士神经内分泌肿瘤服务的转变实现小肠神经内分泌肿瘤(SI-NETs)的早期诊断。
J Neuroendocrinol. 2025 Apr;37(4):e13486. doi: 10.1111/jne.13486. Epub 2024 Dec 26.
3
High Prevalence of Sarcopenia in Patients with Newly Diagnosed Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs), but No Association with the Risk of Surgical Complications.
新诊断的胃肠胰神经内分泌肿瘤(GEP-NETs)患者中肌肉减少症的患病率很高,但与手术并发症风险无关。
Nutrients. 2024 Nov 5;16(22):3790. doi: 10.3390/nu16223790.
4
The Clinicopathological Characteristics and Surgical Treatment of Gastrointestinal Neuroendocrine Neoplasm-A 10-Year Single-Center Experience.胃肠道神经内分泌肿瘤的临床病理特征及外科治疗——单中心10年经验
J Clin Med. 2024 Aug 19;13(16):4892. doi: 10.3390/jcm13164892.
5
Identifying patients with undiagnosed small intestinal neuroendocrine tumours in primary care using statistical and machine learning: model development and validation study.利用统计和机器学习在初级保健中识别未确诊的小肠神经内分泌肿瘤患者:模型开发和验证研究。
Br J Cancer. 2024 Jul;131(2):305-311. doi: 10.1038/s41416-024-02736-1. Epub 2024 Jun 3.
6
Sarcopenia and Neuroendocrine Neoplasms.肌肉减少症与神经内分泌肿瘤。
Curr Oncol Rep. 2024 Feb;26(2):121-128. doi: 10.1007/s11912-024-01494-w. Epub 2024 Jan 25.
7
Function of microRNA‑124 in the pathogenesis of cancer (Review).微小 RNA-124 在癌症发病机制中的功能(综述)。
Int J Oncol. 2024 Jan;64(1). doi: 10.3892/ijo.2023.5594. Epub 2023 Dec 1.
8
Platelet-derived circRNAs signature in patients with gastroenteropancreatic neuroendocrine tumors.血小板衍生的 circRNAs 特征在胃肠胰神经内分泌肿瘤患者中。
J Transl Med. 2023 Aug 16;21(1):548. doi: 10.1186/s12967-023-04417-8.
9
Prevalence of Sarcopenia and Impact on Survival in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours.转移性胃肠胰神经内分泌肿瘤患者的肌肉减少症患病率及其对生存的影响
Cancers (Basel). 2023 Jan 27;15(3):782. doi: 10.3390/cancers15030782.
10
Neuroendocrine tumours: what gastroenterologists need to know.神经内分泌肿瘤:胃肠病学家需要了解的内容。
Frontline Gastroenterol. 2020 Sep 22;13(1):50-56. doi: 10.1136/flgastro-2020-101431. eCollection 2022.